Peptide Science
Peptide Science

Coming Off: The Washout Window

May 03, 2026
washoutcyclingdiscontinuationreboundoff-cycle

Most peptide protocols are written from the on-cycle side: doses, timing, what to expect during the run. The washout - the off-cycle stretch between runs - gets less attention. That's where most of the community's bad decisions get made: panic-restarts when natural variation looks like "the protocol stopped working," doubling-up when a bloodwork result drifts during the natural return-to-baseline, and abandonment of cycle discipline because the off-cycle felt unnecessary. This article covers what actually happens during a washout, by class, so the off-cycle is part of the protocol rather than a gap in it.

For the on/off rationale and why cycling matters in the first place, see Cycling Strategies. For the GLP-1-specific muscle-preservation framing during taper, see GLP-1 and Muscle Preservation.

What "washout" means and what it's for

Washout is the off-period between cycles. Two purposes. First, receptor recovery - chronically stimulated receptors downregulate; an off-period lets receptor density and sensitivity reset. Second, cumulative exposure management - for compounds with long-horizon risks (angiogenic peptides, supraphysiologic IGF-1), intermittent exposure is meaningfully different from continuous exposure on the risk axis.

Washout is not the same as "the compound is gone from your system." Most peptides have plasma half-lives of hours; they're cleared in a day or two. The washout window is the time it takes the downstream signalling to return to baseline - IGF-1 levels, receptor expression, immune tone, satiety set-point. That can be days for some classes and weeks for others.

Per-class washout expectations

GH-axis (Mod GRF, Ipamorelin, Sermorelin, CJC-1295, Tesamorelin)

  • IGF-1 return-to-baseline: 4–6 weeks after the last dose, typically. The pulsatile-GHRH stack architecture leaves the pituitary axis intact, so recovery is a downward drift rather than a rebound.
  • What you'll feel: recovery between training sessions returns to pre-cycle baseline at week 2–4. Sleep depth drifts back. No "withdrawal" pattern; just gradual loss of the on-cycle signal.
  • Bloodwork timing: draw IGF-1 at week 4–6 of washout to confirm return-to-baseline. If IGF-1 stays elevated past 8 weeks, that's worth investigating with a clinician.
  • Body comp: any modest gains (improved sleep-driven recovery, slightly better lean mass retention) hold for weeks but drift back over months without the signal. The cycle was the contribution, not the maintenance.

Continuous-elevation (CJC-1295 DAC, somatropin)

  • IGF-1 return-to-baseline: longer - 6–10 weeks for DAC-CJC, 4–6 for somatropin. The DAC chain extends GH elevation past the dosing window, so the signal lingers further.
  • Recovery question is real for somatropin. Long high-dose somatropin runs can transiently suppress endogenous GH pulse architecture. Recovery to pre-cycle pulsatile output happens but takes months in some users. Sermorelin or Mod GRF + Ipamorelin bridge protocols are sometimes used for users who ran high-dose somatropin for extended periods; not the default for short cycles.
  • Body-comp drift: faster than pulsatile-stack coming-off because the on-cycle effect was larger. The first 8–12 weeks post-cycle are when most of the visible regression happens.

GLP-1 family (Semaglutide, Tirzepatide, Retatrutide, Liraglutide)

  • Half-life and lingering effect: for the long-acting weekly compounds (semaglutide ~7d, tirzepatide ~5d, retatrutide ~6d), measurable serum levels persist 4–6 weeks. Appetite suppression fades on a similar timeline.
  • Appetite rebound is real. The "food noise gets loud again" reports start at week 3–5 for most users. The body's set-point hasn't moved; only the signal that suppressed it has.
  • Weight regain. The most-studied finding from STEP discontinuation trials: roughly two-thirds of cut weight returns within 12 months of stopping if no maintenance protocol is in place. This is the load-bearing data point - taper to ~50% of cutting dose for 6–12 months before discontinuing entirely is the community discipline. See GLP-1 and Muscle Preservation for muscle-loss specifics during the same window.
  • Bloodwork: HbA1c and fasting glucose may drift upward in 4–8 weeks if no metabolic foundation work was done during the on-cycle. The cycle didn't change baseline glucose tolerance, only masked it.

Growth factor class (IGF-1 LR3, IGF-1 DES, PEG-MGF)

  • 4-week blast β†’ 4-week washout is the standard discipline. After a 4-week LR3 blast, IGF-1 returns to baseline in 2–3 weeks; receptor sensitivity recovers over the full 4-week off-period.
  • Hypoglycemia risk gone within days. The acute safety profile resolves quickly once dosing stops; the long-horizon growth-pathway risk is what cycling is actually managing.
  • Body comp drift: any visible muscle-mass gain holds for weeks but the rate of acquisition stops. LR3 was the accelerator; without it, you're back to AAS-and-training pace.

Healing peptides (BPC-157, TB-500, GHK-Cu systemic)

  • Cycle is for an injury or procedure window. Washout is the rest of the year. There's no on-cycle effect to maintain because the cycle was a tool for a specific repair window that's now closed.
  • What you might notice: small joint or tendon discomfort that the on-cycle was masking can resurface. That's a signal the underlying condition wasn't fully resolved, not a "withdrawal" from the peptide.
  • Cumulative-exposure framing applies. The angiogenic load from BPC + TB-500 is intermittent rather than continuous, which is the protective design of the cycle. See Cancer Risk and Growth Factors.

Melanocortin (Melanotan II, PT-141)

  • MT-II pigment persists. The acquired tan from a loading + maintenance cycle holds for months. There's no rapid fade-back because melanin in melanocytes is the storage; UV exposure during washout maintains it longer than expected.
  • Side effects fade fast. Nausea, flushing, spontaneous erection effects all resolve within days of stopping. The cycle was titrated to tolerance; off-cycle resets the tolerance.
  • PT-141 has no real washout - it's used on-demand, not chronically. "Stopping" PT-141 just means not using it; no discontinuation effect.

Cognitive (Selank, Semax)

  • No withdrawal pattern. Stop using the spray; the effect fades over the next 24 hours and that's it. No rebound anxiety, no rebound brain fog.
  • Selank's situational effect remains accessible. Chronic use can blunt the situational dose; an off-period restores responsiveness within 2 weeks. This is one of the few peptides where washout actively makes the on-cycle better.

What to track during washout

  • IGF-1 + HbA1c at weeks 4–8 if you ran a GH-axis, growth-factor, or supraphysiologic-IGF protocol. Confirms the return-to-baseline; flags any persistent drift.
  • Body weight, weekly. Especially important for GLP-1 washouts where the regain pattern is well-studied. Tracking the rate of regain (gradual vs sharp) tells you whether the foundation work during on-cycle stuck.
  • Sleep tracker (RHR, deep sleep). GH-axis cycles show their loss most cleanly in sleep tracker data - RHR drifts upward 2–4 bpm and deep-sleep fraction drops over 2–4 weeks. That's expected, not a problem.
  • Subjective journal. Mood, motivation, recovery quality. The signal is noisier than bloodwork but catches things that don't move objective markers.
  • Resting BP for melanocortin runs. Confirms return to pre-cycle baseline; flags any persistent drift.

Common washout mistakes

  • Panic-restarting at week 3. The "I lost the benefit overnight" framing is almost always reading natural week-to-week variation as cycle loss. The washout is the protocol; finishing it is the protocol. Re-starting before the receptor recovery happens defeats the purpose of cycling.
  • Doubling up the next cycle to "make up" for the washout. The next cycle should be the same dose as the last successful one, not double. Cumulative-exposure risk doesn't care about the per-cycle effort to compensate; it tracks total drug-time integrated over weeks.
  • Discontinuing a GLP-1 cold-turkey from cutting dose. The taper to maintenance is the protocol, not the afterthought. Roughly 60% of cut weight regained within 12 months is the discontinuation-trial finding. Plan for the maintenance phase before the cut.
  • Skipping bloodwork during washout. The off-cycle is when you confirm reversibility. If IGF-1 stays elevated, HbA1c keeps drifting, or hematocrit doesn't normalise, that's data you need before the next cycle. Skipping it loses the most informative bloodwork window.
  • Treating off-cycle as "wasted time." The off-cycle is when the receptor density returns, the tissue repairs from on-cycle stress, and your body's natural endocrine rhythms reset. For protocols where on-cycle has accumulated load (somatropin suppression, IGF-1 supraphysiologic exposure, melanocortin autonomic load), the off-cycle is doing real work even when it feels like nothing's happening.

Decision frame for re-starting

  1. Has the off-cycle reached its planned duration?
    β†’ No β†’ finish it. Don't restart early without a specific reason.
    β†’ Yes β†’ continue.
  2. Did bloodwork drift back to baseline?
    β†’ Yes β†’ safe to restart at the previous dose.
    β†’ No β†’ extend the washout 2–4 weeks; re-test.
  3. Is there a clinical reason to restart now (acute injury, upcoming competition, etc.)?
    β†’ Yes β†’ coordinate the restart timing around the trigger; consider whether a different compound class fits the new context.
    β†’ No β†’ restart on the original schedule.
  4. Are you restarting because you "miss the feeling" rather than for an objective reason?
    β†’ That's a flag to extend the washout, not shorten it. The feeling-of-missing-it pattern is what receptor downregulation is designed to manage; restarting earlier compounds the underlying issue.

Cross-references

Coming Off: The Washout Window